{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:50Z","timestamp":1786982750498,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40261-022-01130-0","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T01:24:54Z","timestamp":1646097894000},"page":"301-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6720-2756","authenticated-orcid":false,"given":"Alok","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh Kumar","family":"Balasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"issue":"5","key":"1130_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1358\/dof.2020.45.5.3123467","volume":"45","author":"P Martelletti","year":"2020","unstructured":"Martelletti P, Cipolla F, Capi M, et al. Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, preventive treatment of migraine. Drugs Fut. 2020;45(5):285.","journal-title":"Drugs Fut."},{"key":"1130_CR2","unstructured":"Kumar A, Kadian R. Migraine Prophylaxis. [Updated 2021 Oct 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507873\/."},{"key":"1130_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s10194-019-1072-2","volume":"21","author":"CH G\u00f6bel","year":"2020","unstructured":"G\u00f6bel CH, Karstedt SC, M\u00fcnte TF, et al. ICHD-3 is significantly more specific than ICHD-3 beta for diagnosis of migraine with aura and with typical aura. J Headache Pain. 2020;21:2.","journal-title":"J Headache Pain"},{"issue":"1","key":"1130_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1129-2377-14-1","volume":"14","author":"TJ Steiner","year":"2013","unstructured":"Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14(1):1.","journal-title":"J Headache Pain"},{"issue":"19","key":"1130_CR5","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"AM Migraine","year":"2020","unstructured":"Migraine AM. N Engl J Med. 2020;383(19):1866\u201376.","journal-title":"N Engl J Med"},{"key":"1130_CR6","doi-asserted-by":"publisher","first-page":"174480691876769","DOI":"10.1177\/1744806918767697","volume":"14","author":"M Su","year":"2018","unstructured":"Su M, Yu S. Chronic migraine: a process of dysmodulation and sensitization. Mol Pain. 2018;14:1744806918767697. https:\/\/doi.org\/10.1177\/1744806918767697.","journal-title":"Mol Pain"},{"issue":"10127","key":"1130_CR7","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","volume":"391","author":"DW Dodick","year":"2018","unstructured":"Dodick DW. Migraine Lancet. 2018;391(10127):1315\u201330.","journal-title":"Migraine. Lancet."},{"key":"1130_CR8","unstructured":"Atogepant (Qulipta)\u2014FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=215206Last. Accessed 6 Nov 2021."},{"key":"1130_CR9","unstructured":"Buckingham L. EMEA-002530-PIP01-18 [Internet]. European Medicines Agency. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-002530-pip01-18. Accessed 6 Nov 2021."},{"issue":"6","key":"1130_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40261-021-01034-5","volume":"41","author":"R Boinpally","year":"2021","unstructured":"Boinpally R, Spaventa J, Chen K, Butler M. Evaluation of the pharmacokinetic interaction and safety of atogepant co-administered with acetaminophen or naproxen in healthy participants: a randomized trial. Clin Drug Investig. 2021;41(6):557\u201367.","journal-title":"Clin Drug Investig"},{"key":"1130_CR11","unstructured":"Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf. Accessed 29 Oct 2021."},{"issue":"7","key":"1130_CR12","first-page":"726","volume":"10","author":"R Boinpally","year":"2021","unstructured":"Boinpally R, Jakate A, Butler M, Borbridge L, Periclou A. Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase 1 trial. ClinPharmacol Drug Dev. 2021;10(7):726\u201333.","journal-title":"ClinPharmacol Drug Dev."},{"issue":"9","key":"1130_CR13","first-page":"1157","volume":"60","author":"W Ankrom","year":"2020","unstructured":"Ankrom W, Xu J, Vallee MH, et al. Atogepant has no clinically relevant effects on the pharmacokinetics of an ethinyl estradiol\/levonorgestrel oral contraceptive in healthy female participants. J ClinPharmacol. 2020;60(9):1157\u201365.","journal-title":"J ClinPharmacol."},{"issue":"15 Supplement","key":"1130_CR14","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1212\/WNL.96.15_supplement.1140","volume":"96","author":"M Butler","year":"2021","unstructured":"Butler M, Jakate A, Periclou A, Boinpally R. Co-administration of single therapeutic oral doses of atogepant and sumatriptan produces no clinically relevant drug-drug interactions. Neurology. 2021;96(15 Supplement):1140.","journal-title":"Neurology"},{"issue":"S1","key":"1130_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.14130","volume":"61","author":"R Boinpally","year":"2021","unstructured":"Boinpally R, Butler M, Borbridge L, Wangsadipura V, Papinska A. Evaluation of the pharmacokinetic interaction and safety of atogepant coadministered with esomeprazole magnesium. Headache. 2021;61(S1):1\u2013178. https:\/\/doi.org\/10.1111\/head.14130.","journal-title":"Headache"},{"issue":"2","key":"1130_CR16","first-page":"599","volume":"14","author":"KC Min","year":"2021","unstructured":"Min KC, Kraft WK, Bondiskey P, et al. Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults. ClinTransl Sci. 2021;14(2):599\u2013605.","journal-title":"ClinTransl Sci."},{"issue":"9","key":"1130_CR17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/cpdd.940","volume":"10","author":"R Boinpally","year":"2021","unstructured":"Boinpally R, McNamee B, Yao L, et al. A single supratherapeutic dose of atogepant does not affect cardiac repolarization in healthy adults: results from a randomized, single-dose, phase 1 crossover trial. ClinPharmacol Drug Dev. 2021;10(9):1099\u2013107. https:\/\/doi.org\/10.1002\/cpdd.940.","journal-title":"ClinPharmacol Drug Dev."},{"issue":"9","key":"1130_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol. 2020;19(9):727\u201337.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1130_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695\u2013706.","journal-title":"N Engl J Med"},{"key":"1130_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1130_CR21","unstructured":"Dodick DW,\u00a0Pozo-Rosich P,\u00a0Blumenfeld AM, et al. Atogepant improved patient-reported migraine-specific quality of life in a 12-week phase 3 (ADVANCE) trial for preventive treatment of migraine (1459). Neurology. 2021;96\u00a0(15 Supplement):1459"},{"key":"1130_CR22","unstructured":"Lipton RB, Pozo-Rosich P, Blumenfeld AM, et al. Atogepant improved patient-reported outcome (PRO) measures of activity impairment in migraine-diary and headache impact test in a 12-week, double-blind, randomized phase 3 (ADVANCE) trial for preventive treatment of migraine (1454). Neurology. 2021;96\u00a0(15 Supplement):1454."},{"issue":"1","key":"1130_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","volume":"42","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022;42(1):3\u201311.","journal-title":"Cephalalgia"},{"key":"1130_CR24","unstructured":"A phase 3, multicenter, open-label, 12-week study to evaluate the safety and tolerability of oral atogepant for the prevention of migraine in Chinese participants with chronic migraine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04829747. Accessed 29 Oct 2021."},{"key":"1130_CR25","unstructured":"A phase 3, multicenter, open-label 52-week extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04686136. Accessed 29 Oct 2021."},{"key":"1130_CR26","unstructured":"Phase 3, multicenter, open-label 52-week extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in Japanese participants with chronic or episodic migraine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04437433. Accessed 29 Oct 2021."},{"key":"1130_CR27","unstructured":"A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of atogepant for the prevention of chronic migraine (progress). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03855137. Accessed 29 Oct 2021."},{"key":"1130_CR28","unstructured":"A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of oral atogepant for the prophylaxis of migraine in participants with episodic migraine who have previously failed 2 to 4 classes of oral prophylactic treatments (ELEVATE). Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04740827. Accessed 29 Oct 2021."},{"key":"1130_CR29","unstructured":"A phase 1b, open-label, fixed-sequence, safety, tolerability and drug-drug interaction study between atogepant and ubrogepant in participants with a history of migraine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04818515. Accessed 29 Oct 2021."},{"key":"1130_CR30","unstructured":"A phase 3, multicenter, open-label 40-week extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03939312. Accessed 29 Oct 2021."},{"key":"1130_CR31","unstructured":"A phase 3, multicenter, randomized, open-label study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03700320. Accessed 29 Oct 2021."},{"key":"1130_CR32","doi-asserted-by":"crossref","unstructured":"AshinaM, Tepper SJ, Reuter U, et al. Long-term safety and tolerability of atogepant 60 mg following once daily dosing over 1 year for the preventive treatment of migraine. J Headache Pain. 2021;22(Suppl 1):P089","DOI":"10.1017\/cjn.2021.312"},{"key":"1130_CR33","doi-asserted-by":"crossref","unstructured":"AshinaM, Tepper SJ, Reuter U, et al. Long-term safety and tolerability of atogepant 60 mg following once daily dosing over 1 year for the preventive treatment of migraine. Eur J Neurol. 2021;28(Suppl 1):OPR-134","DOI":"10.1017\/cjn.2021.312"},{"key":"1130_CR34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40267-019-00664-2","volume":"35","author":"A Singh","year":"2019","unstructured":"Singh A, Thangaraju P, Dhaneria SP. Recent and updated pharmacotherapy of migraine. Drugs Ther Perspect. 2019;35:571\u20138.","journal-title":"Drugs Ther Perspect."},{"issue":"1","key":"1130_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s10194-021-01366-9","volume":"22","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E, et al. In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain. 2021;22(1):151.","journal-title":"J Headache Pain"},{"key":"1130_CR36","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","volume":"2","author":"A Singh","year":"2020","unstructured":"Singh A, Gupta D, Sahoo AK. Acute migraine: can the new drugs clinically outpace? SN ComprClin Med. 2020;2:1132\u20138.","journal-title":"SN ComprClin Med"},{"issue":"1","key":"1130_CR37","first-page":"17","volume":"99","author":"H Ha","year":"2019","unstructured":"Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019;99(1):17\u201324.","journal-title":"Am Fam Physician"},{"issue":"Suppl 1","key":"1130_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/head.13305","volume":"58","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58(Suppl 1):33\u201347.","journal-title":"Headache"},{"issue":"1","key":"1130_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1526-4610.2010.01799.x","volume":"51","author":"KM Connor","year":"2011","unstructured":"Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011;51(1):73\u201384.","journal-title":"Headache"},{"issue":"5","key":"1130_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"HC Diener","year":"2011","unstructured":"Diener HC, Barbanti P, Dahl\u00f6f C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31(5):573\u201384.","journal-title":"Cephalalgia"},{"key":"1130_CR41","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3389\/fphar.2019.00795","volume":"10","author":"F Xu","year":"2019","unstructured":"Xu F, Sun W. Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine. Front Pharmacol. 2019;10:795. https:\/\/doi.org\/10.3389\/fphar.2019.00795.","journal-title":"Front Pharmacol"},{"issue":"S1","key":"1130_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.14130","volume":"61","author":"E Popoff","year":"2021","unstructured":"Popoff E, Powell L, Johnston KM, et al. Rimegepant versus atogepant and monoclonal antibody treatments for the prevention of migraine: a systematic literature review and network meta-analysis. Headache. 2021;61(S1):1\u2013178. https:\/\/doi.org\/10.1111\/head.14130.","journal-title":"Headache"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01130-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01130-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01130-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T10:48:16Z","timestamp":1726742896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01130-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1130"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01130-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"3 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to assist in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Alok Singh and Mahesh Kumar Balasundaram have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed equally to this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}